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Background: In a number of human malignancies, tumor-associated macrophages (TAMs) are closely involved in tumor
progression. On the other hand, dendritic cells (DCs) that infiltrate tumor tissues are involved in tumor suppression.
However, there have been very few reports on the distribution profiles of TAMs and DCs in thymic epithelial tumors. We
examined the difference in the distribution profiles between TAMs and DCs in thymoma and thymic carcinoma.
Methods: We examined 69 samples of surgically resected thymic epithelial tumors, namely, 16 thymic carcinomas and
53 thymomas, in which we immunohistochemically evaluated the presence of TAMs using CD68 and CD163 as markers
and DCs using S100 as the marker in tumor tissue samples in comparison with normal thymic tissues.
Results: The percentage of samples with a large number of CD68+ TAMs was not significantly different between thymic
carcinoma and thymoma (7/16 versus 16/53, p = 0.904). However, the percentage of sample with a large number of
CD163+ TAMs was significantly higher in thymic carcinoma than in thymoma (15/16 versus 34/53, p = 0.024). In contrast,
the percentage of samples with a large number of S100+ DCs was significantly lower in thymic carcinoma than in
thymoma (2/16 versus 23/53, p = 0.021).
Conclusions: To the best of our knowledge, we are the first to show a high percentage of CD163+ TAMs and a low
percentage of S100+ DCs in thymic carcinoma samples, and our findings may provide an idea for future targeted
therapeutic strategies for thymic carcinoma using antibodies that inhibit monocyte differentiation to TAMs, thereby
skewing TAMs differentiation toward DCs.
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Macrophages that infiltrate tumor tissues are referred to as
tumor-associated macrophages (TAMs) and are closely
involved in tumor progression by inducing angiogenesis,
immunosuppression, and invasion [1]. The protumoral role
of TAMs is supported by many clinical studies of carcin-
omas, including breast, prostate, endometrial, and bladder
carcinomas, and malignant lymphomas, which showed a* Correspondence: m.omatsu@med.showa-u.ac.jp
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unless otherwise stated.correlation between a large number of macrophages and
poor prognosis [2,3]. On the other hand, dendritic cells
(DCs) that infiltrate tumor tissues are involved in tumor
suppression via immune responses. A large number of
DCs is related to better survival in a variety of malignant
tumors such as melanoma, breast carcinoma, hepatocellu-
lar carcinoma, and lung adenocarcinoma [4].
Thymic epithelial tumors are rare mediastinal tumors
and can be classified into thymoma and thymic carcin-
oma. Compared with other organs, the human thymus is
a lymphoepithelial organ, and macrophages and DCs, as
well as epithelial cells, are the cellular components; how-
ever, there have been very few reports [5] concerningl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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immunohistochemically examined tumor tissue samples
to characterize TAMs and DCs in thymoma and thymic
carcinoma by comparing them with those in normal
thymic tissues.Methods
Patients and samples
In this study, we examined samples from 69 patients di-
agnosed and treated for primary thymic epithelial tumors
at Showa University Northern Yokohama Hospital, Showa
University Hospital, and Showa University Fujigaoka
Hospital from August 2003 to June 2014. The samples
were obtained by surgical resection without neoadjuvant
therapy from 16 patients with thymic carcinoma (Figure 1B)
(10 males and 6 females; age range, 34–79 years, including
no myasthenia gravis patient) and 53 patients with thym-
oma (Figure 1A) (28 males and 25 females; age range, 30–
83 years, including 9 myasthenia gravis patients). Follow-up
data were available for 62 patients, including 9 with thymic
carcinoma and 53 with thymoma. At the time of analysis,
only one of the 9 patients with thymic carcinoma died of
disease, one alive with recurrence, and 7 with alive without
recurrence, the other hand, only one of the 53 patients with
thymoma died of disease, three alive with recurrence and
49 alive without recurrence (Table 1). All of the tissue sam-
ples were fixed in 20% formalin, routinely processed, em-
bedded in paraffin wax, cut into 3-μm-thick sections, and
stained with hematoxylin and eosin (HE). Thymoma was
the diagnosis when immature T cell markers, such as CD99
and TdT, were stained in the underlying lymphocytes, and
thymic carcinoma was the diagnosis when CD5 and c-kit
were stained in epithelial cells. This study was approved
by the Ethics Committee of Showa University Northern
Yokohama Hospital (No.#1406-02).Immunohistochemical staining
A list of antibodies with their clones, sources, dilu-
tions, antigen retrieval methods, and incubation dura-
tions is presented in Table 2. After endogenous
peroxidase activity was inhibited in the prepared sec-
tions using hydrogen peroxide solution, the sections
were incubated with the appropriate primary antibody. A
secondary antibody was raised against biotinylated im-
munoglobulin and conjugated with avidin-horseradish
peroxidase (HRP). The staining of each sample was visual-
ized using a Ventana I-View DAB universal kit (Roche,
Tokyo, Japan). The antibody-antigen reaction was en-
hanced using copper sulfate, after nuclear staining with
Mayer’s hematoxylin. Positive controls for the antibodies
were prepared in accordance with the manufacturer’s
instruction.Evaluation of immunohistochemical staining
For the enumeration of CD68+, CD163+ TAMs and
S100+ DCs, ten representative fields were examined at
high-power magnification (400×). Only CD68+, CD163+
cells showing a macrophagic morphology, and only S100+
cells showing a dendritic morphology were counted. The
percentages of positively stained TAMs and DCs were
calculated in relation to overall cellularity [6-8] using
hard-copy photomicrographs. The cells were counted in
duplicate by two different pathologists (M.O. and T.K.)
without knowledge of the patients’ clinical data. The ob-
tained data were then averaged and defined as the TAM
and DC contents of the samples. Normal thymic samples
obtained distal to the tumor site from 34 patients (18
males and 16 females; age range, 38-83 years) were used
as the controls. The median percentage of markers-
positive macrophages or DCs in normal thymic samples
was used as the cut-off point to categorize the thymic epi-
thelial tumor samples into the group with a low percent-
age of marker-positive TAMs of DCs and that with a high
percentage of these cells.
Statistical analysis
The variables measured in this study were tested for as-
sociations using the Chi-squared test Fisher’s exact prob-
ability test and Mann-Whitney’s U test. A p value <0.05
was considered statistically significant.
Results
CD68+ TAM
The percentage of CD68+ macrophages varied from 0.11%
to 5.29% with a median of 1.31% in normal thymic sam-
ples. The percentage of CD68+ TAMs varied from 0.13%
to 7.54% with a median of 0.96% in thymoma samples
(Figure 1C), and 0.00% to 7.91% with a median of 1.08% in
thymic carcinoma samples (Figure 1D). Regarding the
positivity for CD68, the thymoma and thymic carcinoma
samples were categorized into two groups on the basis of
the 1.31% cut-off point that indicates the median in nor-
mal thymic samples. A high percentage of CD68+ TAMs
was observed in 43.8% (7/16) of thymic carcinoma sam-
ples and 30.2% (16/53) of thymoma samples (including 3
type A, 3 type AB, 5 type B1, 2 type B2 and 3 type B3),
which were not statistically significantly different (p =
0.904) (Table 3a).
The correlations between percentage of CD68+ TAMs
and the stage categories in thymoma and thymic carcin-
oma were shown in Table 4, which were not statistically
significantly different (p = 0.853 and p = 0.262) (Table 4a).
CD163+ TAM
The percentage of CD163+ macrophages varied from
4.95% to 10.4% with a median of 7.28% in normal thymic
samples. The percentage of CD163+ TAMs varied from
Figure 1 Photomicrographs of thymic lesions. A: High-power view of type B2 thymoma showing polygonal, medium-sized tumor cells associated
with lymphocytes (H&E staining). B: High-power view of thymic carcinoma showing large polyhedral tumor cells with eosinophillic cytoplasm and
apparent nuclei (H&E staining). C: High-power view of type B2 thymoma showing 1.50% of cells immunohistochemically stained positive for CD68
(immunohistochemistry). D: High-power view of thymic carcinoma showing 1.16% of cells immunohistochemically stained positive for CD68
(immunohistochemistry). E: High-power view of type B2 thymoma showing 6.95% of cells immunohistochemically stained positive for
CD163 (immunohistochemistry). F: High-power view of thymic carcinoma showing 35% of cells immunohistochemically stained positive for
CD163 (immunohistochemistry). G: High-power view of type B2 thymoma showing 2.83% of cells immunohistochemically stained positive
for S100 (immunohistochemistry). H: High-power view of thymic carcinoma showing 1.30% of cells immunohistochemically stained positive
for S100 (immunohistochemistry).
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Table 1 Characteristics of patients with thymoma and
thymic carcinoma
Characteristic Thymoma Thymic carcinoma
Patient, n 53 16
Gender, male/female 28/25 10/6












Stage: Based on WHO classification.
SCC: squamous cell carcinoma.
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samples (Figure 1E), and 6.53% to 33.26% with a median
of 14.55% in thymic carcinoma samples (Figure 1F). Re-
garding the positivity for CD163, the thymoma and
thymic carcinoma samples were categorized into two
groups on the basis of the 7.28% cut-off point that indi-
cates the median in normal thymic samples. A high per-
centage of CD163+ TAMs was observed in 93.8% (15/
16) of thymic carcinoma samples and 64.2% (34/53) of
thymoma samples (including 2 type A, 12 type AB, 6
type B1, 10 type B2 and 4 type B3), which were statisfi-
cally significantly different (p = 0.024) (Table 3b). More-
over, the percentage of samples with a large number of
CD163+ TAMs was higher in the thymic carcinoma
samples than in the thymoma samples.
The correlations between percentage of CD163+
TAMs and the stage categories in thymoma and thymic
carcinoma were shown in Table 4, which were not statis-
tically significantly different (p = 0.754 and p = 0.138)
(Table 4b).
S100+ DCs
The percentage of S100+ DCs varied from 0.41% to 5.02%
with a median of 1.50% in normal thymic samples, 0.13%
to 4.45% with a median of 1.28% in thymoma samplesTable 2 Antibodies used for immunohistochemical analysis
Antibody Clone Source Dilution
CD68 KP-1 DAKO Prediluted
CD163 10D6 Leica NOVO 1:100
S100 protein 4C4.9 VENTANA Roche Prediluted(Figure 1G), and 0.06% to 3.99% with a median of 0.79%
in thymic carcinoma samples (Figure 1H). Regarding the
positivity for S100, the thymoma and thymic carcinoma
samples were categorized into two groups on the basis of
the 1.50% cut-off point that indicates the median in normal
thymic samples. A high percentage of S100+ DCs was ob-
served in 12.5% (2/16) of thymic carcinoma samples and
43.4% (23/53) of thymoma samples (including 1 type A, 4
type AB, 5 type B1, 9 type B2 and 4 type B3), which were
statistically significantly different (p = 0.021) (Table 3c).
Moreovers, the percentage of samples with a large number
of S100+ DCs was higher in the thymoma samples than in
the thymic carcinoma samples.
The correlations between percentage of S100+ DCs and
the stage categories in thymoma and thymic carcinoma
were shown in Table 4, which were not statistically signifi-
cantly different (p = 0.279 and p = 0.691) (Table 4c).
Discussion
Macrophages are found in the cellular microenviron-
ment of many carcinomas, and these TAMs represent a
heterogeneous population of functionally distinct cells
[2] that may affect the neoplastic process. Different phe-
notypes, as well as different cytokine secretion profiles,
have suggested a distinction between ‘proinflammatory
M1’ and ‘immunosuppressive M2’ macrophages [9]. Al-
though it is now acknowledged that the binary M1/M2
model is oversimplified [10,11] and that there is a
spectrum of intermediate macrophage phenotypes in re-
sponse to various local microenvironmental signals
[12,13], TAMs most often seem to exhibit M2 features
[14]. However, at present, there is no single marker for
macrophage polarization [15].
In the tumor microenvironment, TAMs play a key role
in carcinoma-associated inflammation and affect the pro-
gression and prognosis of various tumor types [16,17]
other than colorectal-gastric carcinoma and osteosarcoma
[1], and a dense macrophage infiltrate is associated with
enhanced nodal metastases, distant metastases, and re-
duced recurrence-free survival [18]. On the other hand,
there have been only a few reports comparing the TAMs
in malignant tumors with those in benign tumors arising
in the same organs. In ovarian tumors, the number of
CD68+, CD163+ TAMs is reported to show a stepwise in-
crease from benign, borderline to malignant [19]. In thy-
roid tumors, the number of CD68+ TAMs is also higher
in papillary carcinoma than in follicular adenomas [20]. InAntigen retrieval Incubation (min)
Protease (0.5 unit/ml) for 8 min 32
Heat treatment of EDTA for 30 min 32
Not required 16
Table 3 Percentage of samples showing CD68, CD163,
and S100 expression in thymoma and thymic carcinoma
Low High p-value
(a) CD 68 Thymoma 37 16 0.904
(A/AB/B1/B2/B3) (0/11/12/12/2) (3/3/5/2/3)
thymic carcinoma 9 7
(b) CD 163 Thymoma 19 34 0.024
(A/AB/B1/B2/B3) (1/2/11/4/1) (2/12/6/10/4)
thymic carcinoma 1 15
(c) S100 Thymoma 30 23 0.021
(A/AB/B1/B2/B3) (2/10/12/5/1) (1/4/5/9/4)
thymic carcinoma 14 2
The median percentages of marker-positive TAMs or DCs in normal thymic
samples, (1.31% for CD68, 7.28% for CD163, and 1.50% for S100), were used as
the cut-off points to categorize the samples into the group with a low percentage
of marker-positive TAMs or DCs ant that with high percentage of these cells.
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ing TAMs between thymoma and thymic carcinoma, in
this study, we confirmed previous findings for thymic epi-
thelial tumor. Although the percentage of CD68+ TAMs
was not significantly different between thymoma and
thymic carcinoma, in thymic carcinoma, which is associ-
ated with more frequent invasive growth and distant me-
tastases, a higher percentage of CD163+ TAMs was
found. These observations suggest that malignant tumorsTable 4 The correlations between percentage of samples
showing CD68, CD163, S100 expression and the stage
categories in thymoma and thymic carcinoma
Thymoma Thymic carcinoma
(a) CD68 Stage Low High p-value Low High p-value
I 21 9 0.853 0 0 0.262
II 11 6 5 2
III 4 1 2 2
IV 1 0 1 2
Thymoma Thymic carcinoma
(b) CD163 Stage Low High p-value Low High p-value
I 10 20 0.754 0 0 0.138
II 7 10 0 7
III 2 3 2 4
IV 0 1 1 2
Thymoma Thymic carcinoma
(c) S100 Stage Low High p-value Low High p-value
I 19 11 0.279 0 0 0.691
II 8 9 6 1
III 3 2 4 0
IV 0 1 2 0
Stage: Based on WHO classification.
2 cases of thymic carcinoma were in unkown stage.harbor a higher percentage of CD163+ TAMs than
benign tumors in their microenvironment, which is a
reasonable finding considering the roles of TAMs in
malignant tumors.
CD68 is a glycoprotein used as a macrophage marker but
is nonspecific. On the other hand, CD163 is a member of
the scavenger receptor family and is specific for macro-
phages [7]. Immunohistochemical studies of TAMs demon-
strated the superiority of CD163 over CD68 in predicting
the clinical outcome [17-19]. We found a higher percentage
of CD163+ TAMs than of CD68+ TAMs in both thymoma
and thymic carcinoma samples, which was consistent with
previous observations in Hodgkin’s lymphoma [7], malig-
nant melanomas [20], and leiomyosarcomas [21]. Thus, the
use of CD68 may lead to underestimation of the true per-
centage of TAMs [18].
DCs, i.e., specialized antigen-presenting cells, play a crit-
ical role in innate and adaptive immune responses [22]. In
the tumor microenvironment, DCs are the most potent
antigen-presenting cells that induce antigen-specific im-
mune responses by engulfing dying tumor cells [23].
Among several DC markers, many investigators have used
S100 as a valuable marker of DCs, because S100 show ad-
equate immunohistochemical staining on paraffin tissue
sections [24]. Several studies showed that the number
of S100+ DCs in colon carcinoma [25], human gastric
carcinoma [26], and esophageal carcinoma [27] negatively
correlates with lymph node metastases, size of tumor, and
survival time, that is, the larger the number of DCs, the
better the patient’s prognosis. In addition to these clinico-
pathological parameters, a recent study of uterine endo-
metrioid adenocarcinoma demonstrated the inverse
correlation between a large number of S100+ DCs and the
histological grade for malignant potential [28].
S100 can also be used as a useful marker of thymic DCs
[29-31]. In thymic tumor, although there has been no
report showing the relationships between the percentage
of DCs and prognosis, the percentage of S100+ DCs was
found to be lower in thymic carcinoma than in thymoma
[5]. On the other hand, using fascin as a mature DC
marker, DCs were reported to appear more frequently in
benign thymic neoplasms [32]. In this study, we also con-
firmed the previous finding of a lower percentage of S100
+ DCs in thymic carcinoma than in thymoma, indicating
that malignant thymic epithelial tumor is associated with a
paucity of DCs in their microenvironment.
Few studies examining the interaction between TAMs
and DCs in malignant tumor are available. In Hodgkin’s
lymphoma cases, a high percentage of TAMs and a low
percentage of DCs were reported to be associated with
adverse prognostic parameters [4]. In a comparison
between benign and malignant skin tumors, malignant
transformation of keratinocytes was found to be associ-
ated with infiltration of TAMs and loss of DCs [33].
Omatsu et al. Diagnostic Pathology  (2014) 9:215 Page 6 of 7Similarly, we found the same correlation, and this is the
first report showing the association of thymic carcinoma
with the increase in the percentage of TAMs and loss of
DCs. Regarding the differentiation of monocytes, the
CD115 (macrophage colony-stimulating factor receptor
or CSF-1 receptor) pathway stimulates their survival and
differentiation into macrophages rather than into DCs
[34,35], and the CD115/CSF-1 pathway is reported to
play a central role in tumor progression through its
effects on the differentiation of TAMs [36]. Concerning
the therapeutic aspects focusing on TAMs and DCs, re-
cent studies revealed that some anti-CD115 monoclonal
antibodies inhibit monocyte differentiation to TAMs,
thereby skewing TAM differentiation toward DCs, and
contributing to the generation of more efficient anti-
tumor immune responses [37]. This study demonstrated
an idea for future targeted therapeutic strategies for
thymic carcinoma using such antibodies competing with
CSF-1 binding to CD115.
Conclusions
We examined the difference in the distribution profiles
between TAMs and DCs in thymic epithelial tumors, and
found a higher percentage of CD163+ TAMs and a lower
percentage of S100+ DCs in thymic carcinoma tissues
than in thymoma tissues. Our findings may provide an
idea for future targeted therapeutic strategies for thymic
carcinoma using antibodies that inhibit monocyte differ-
entiation to TAMs, thereby skewing TAM differentiation
toward DCs.
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